December #192 : Now Available: New Integrase Inhibitor - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


The POZ 100: Celebrating Unsung Heroes

The POZ 100: A-C

The POZ 100: D-F

The POZ 100: G-H

The POZ 100: J-L

The POZ 100: M-O

The POZ 100: P-R

The POZ 100: S-T

The POZ 100: V-Z

Positive Networks

From the Editor

Your Song


Letters-December 2013


Fire in the Blood

POZ Planet

Law of Desire

Do Some Men Want to Get AIDS?

Rocky Road

Public Knowledge

First in the Fight

Remembrance of Things Past

That ’80s Show

Say What? Lee Daniels Edition


Remembering J.C. Suares

Care and Treatment

Now Available: New Integrase Inhibitor

‘Quad’ as Effective as Older Options, Fewer Side Effects

Does HIV Make Addiction More Insidious?

TB Preventative Therapy Lowers Deaths by One Third

FDA OKs First Rapid Test for Acute HIV

GMHC Treatment Issues December 2013

Research Notes

Prevention: Malaria Vaccine Shows Promise

Treatment: Soybean Compound May Fight HIV

Cure: Drug-Free Viral Control in Monkeys

Concerns: Lymphoma Survival Unimproved

POZ Survey Says

Your Voice

POZ Heroes

A Mother’s Love

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2013

Now Available: New Integrase Inhibitor

by Benjamin Ryan

The U.S. Food and Drug Administration has approved Tivicay (dolutegravir), the second antiretroviral (ARV) to hit the market in the integrase strand transfer inhibitor class, after Isentress (raltegravir). Marketed by ViiV Healthcare and manufactured by GlaxoSmithKline, the drug got the green light for use in both treatment-naive and treatment-experienced people with HIV, including those who have taken Isentress. Tivicay was also approved for use in children ages 12 and older who weigh at least88 pounds (40 kilograms) and haven’t taken integrase inhibitors before.

In clinical trials comparing Tivicay to Isentress, the newly approved ARV suppressed HIV as well or better than the older drug. Tivicay is considered a promising alternative because of its once-a-day, 50-milligram dosing, while Isentress requires 400 mg twice a day.

Saying he sees “a lot of very compelling data” for Tivicay’s use, Antonio Urbina, MD, an HIV specialist at the Spencer Cox Center for Health in New York City, praises the drug’s tolerability and its few drug-drug interactions.

“I think there is a lot of excitement about this drug,” he says. “Because, in our field, with the regimens getting simpler and less toxic, the fewer the pills, the better the tolerability, the greater I think their use is going to be.”

Search: Tivicay, antiretroviral, ARV, FDA,

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.